All In Biotech

NDA 010040 · Bracco

Renografin-76

Diatrizoate Meglumine, Diatrizoate Sodium · Injection, Urethral, Ureteral

Last checked: Nov 19, 2026Latest source record: Jul 6, 2015 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1955

Aug 2, 1955

Approved uses

4

Original approval plus efficacy supplements

Registered trials

14

4 Phase 3, 1 recruiting

FAERS reports

158

144 serious, 96 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 23, 2025.

INDICATION Cystografin is indicated for retrograde cystourethrography.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 3, 1984 Supplement 143 · Efficacy
  • Jul 10, 1983 Supplement 107 · Efficacy
  • Sep 27, 1982 Supplement 121 · Efficacy
  • Aug 2, 1955 Original approval · Type 2 New Active Ingredient and Type 4 New Combination
10 products under this application
  • RENOGRAFIN-76 · DIATRIZOATE MEGLUMINE 66%; DIATRIZOATE SODIUM 10% · INJECTABLE, INJECTION · Discontinued
  • CYSTOGRAFIN · DIATRIZOATE MEGLUMINE 30% · SOLUTION, URETHRAL · Prescription
  • RENO-60 · DIATRIZOATE MEGLUMINE 60% · INJECTABLE, INJECTION · Discontinued
  • CYSTOGRAFIN DILUTE · DIATRIZOATE MEGLUMINE 18% · SOLUTION, URETHRAL · Prescription
  • RENOGRAFIN-60 · DIATRIZOATE MEGLUMINE 52%; DIATRIZOATE SODIUM 8% · INJECTABLE, INJECTION · Discontinued
  • RENOVIST · DIATRIZOATE MEGLUMINE 34.3%; DIATRIZOATE SODIUM 35% · INJECTABLE, INJECTION · Discontinued
  • RENO-DIP · DIATRIZOATE MEGLUMINE 30% · INJECTABLE, INJECTION · Discontinued
  • RENOVIST II · DIATRIZOATE MEGLUMINE 28.5%; DIATRIZOATE SODIUM 29.1% · INJECTABLE, INJECTION · Discontinued
  • DIATRIZOATE MEGLUMINE · DIATRIZOATE MEGLUMINE 76% · INJECTABLE, INJECTION · Discontinued
  • RENO-30 · DIATRIZOATE MEGLUMINE 30% · SOLUTION, URETERAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Diatrizoate Meglumine" as an intervention, any sponsor and status, largest first.

All 14 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use85
  • drug ineffective78
  • nausea75
  • pain73
  • rash72
  • confusional state71
  • dyspnoea71
  • treatment failure71
  • wound71
  • therapeutic product effect decreased70
  • pericarditis69
  • psoriatic arthropathy69

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041
20054
20061
20072
20084
20093
20102
20112
20121
20131
20152
20171
20183
20196
20208
20213
20224
20238
202420
202559
202623

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 51 on PubMed

Sponsor: Bracco · Also marketed as Cystografin, Reno-60, Cystografin Dilute, Renografin-60, Renovist

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.